Glioblastoma Multiforme Treatment Market (2025 - 2033) Size, Share & Trends Analysis Report By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field Therapy), By End-use (Hospitals, Ambulatory Surgery Centers), By Region, And Segment Forecasts

Glioblastoma Multiforme Treatment Market Summary

The global glioblastoma multiforme treatment market size was estimated at USD 3.72 billion in 2024 and is projected to reach USD 7.87 billion by 2033, growing at a CAGR of 8.68% from 2025 to 2033. The rising prevalence of Glioblastoma Multiforme (GBM) and its significant clinical burden are critical drivers in the GBM treatment industry.

The incidence of GBM is steadily increasing worldwide, driven by both improved diagnostic capabilities and a genuine rise in the number of cases. Particularly concerning is the increasing impact of GBM on aging populations, as the risk of developing the disease escalates with age. With the global geriatric population continuing to grow, the number of GBM cases is projected to increase, placing additional strain on healthcare systems and underscoring the urgent need for more effective treatment options.

Data from healthcare institutions around the world highlight the growing clinical burden of GBM. For instance, in December 2024, Parkway Cancer Centre in Singapore reported approximately 100 new GBM cases annually, emphasizing the significant strain on the country’s advanced neuro-oncology infrastructure. GBM patients typically require intensive, multidisciplinary care, involving surgery followed by concurrent radiotherapy and chemotherapy. However, relapses are common within months, highlighting the limitations of current treatment approaches. The center's report underscores the importance of continued advancements in personalized medicine, particularly through the integration of genomics and immunotherapies, to address the complexities of GBM treatment.

Moreover, the integration of advanced technologies in neurosurgery is improving GBM patient outcomes, further boosting treatment access in emerging markets. For example, studies have shown that intraoperative MRI (Io-MRI) significantly enhances surgery success by improving tumor resection rates. A 2024 study published in the Journal of Neuro-Oncology found that Io-MRI-assisted surgeries increased gross total resection rates from 33.6% to 49.6%, with patients experiencing lower recurrence rates and longer progression-free survival.

The therapy’s growing global adoption is also being driven by improved access and supportive reimbursement environments. In several countries, health systems have incorporated TTF into covered treatment options, removing financial barriers for eligible patients. By the end  of 2024, Novocure reported over 4,000 active patients on its Optune Gio TTF system globally, with significant user numbers in the U.S., Germany, France, and Japan. This growing patient base demonstrates the expanding clinical confidence and acceptance of TTF therapy across both developed and emerging healthcare markets. Additionally, the therapy's success is encouraging further technological refinements and research into new applications beyond GBM. Together, these trends are reshaping the therapeutic landscape, making TTF a key component of future GBM treatment approaches.

Market Concentration & Characteristics

The glioblastoma multiforme treatment industry exhibits active innovation in targeted therapies, immunotherapies, and delivery platforms addressing the aggressive nature of GBM. Advancements focus on molecularly targeted agents, oncolytic viruses, and tumor-treating fields (TTF) technology. Companies such as Novocure, Bristol Myers Squibb, and Merck are developing new approaches integrating immuno-oncology and precision medicine. Research is also directed toward overcoming the blood–brain barrier through nanoparticle delivery and convection-enhanced administration. Continuous innovation aims to extend survival outcomes beyond standard radiotherapy and temozolomide-based regimens.

Entry into the GBM treatment industry is challenged by the high cost and complexity of oncology drug development. Extensive preclinical and clinical validation is required due to the heterogeneity and recurrence nature of GBM. Limited patient populations make large-scale trials expensive and time-consuming. Established companies with existing oncology portfolios and research collaborations maintain a competitive edge through regulatory experience and brand presence. For new entrants, achieving differentiation requires clinically proven efficacy and safety in combination with current standards of care.

The GBM treatment market is governed by stringent regulatory oversight across major regions to ensure safety, efficacy, and clinical benefit. Regulatory authorities, including the U.S. FDA and EMA, mandate rigorous Phase II and III studies for approval. However, the FDA’s Orphan Drug Designation and Fast Track pathways support accelerated development of novel therapies. Compliance with oncology-specific pharmacovigilance standards adds cost but enhances credibility. Post-approval surveillance remains critical due to the high-risk nature of the patient population.

Standard therapies such as surgical resection, radiation therapy, and chemotherapy (temozolomide) remain the backbone of GBM management. Substitution risk from non-pharmaceutical interventions like surgery and radiotherapy persists, but emerging drug-based modalities are increasingly used in multimodal treatment plans. TTF devices complement rather than replace pharmacologic options. Due to the limited number of approved drugs and the aggressive progression of GBM, substitutes are constrained by disease biology and unmet clinical need.

North America and Europe represent the leading regions due to established oncology infrastructure, access to advanced therapies, and higher clinical trial participation. Asia Pacific is expanding with growing awareness and improved diagnostic capabilities. Companies are focusing on regional partnerships, clinical collaborations, and patient assistance programs to improve treatment accessibility. Expanding R&D centers in emerging markets supports broader enrollment in clinical studies and accelerates regulatory submissions. Global expansion strategies aim to balance innovation access with affordability across regions.

Treatment Insights

The surgery segment dominated the market with a share of 32.71% in 2024, due to its critical role in reducing tumor burden and improving survival outcomes. Surgical resection remains the first-line intervention for eligible patients, offering immediate relief from symptoms caused by mass effect and intracranial pressure. Advancements in image-guided and minimally invasive neurosurgical techniques have significantly enhanced the precision and safety of tumor removal. High adoption of neuronavigation systems and intraoperative MRI further supports optimal resection while preserving neurological function. Leading cancer centers globally prioritize surgery as the cornerstone of multimodal treatment strategies for glioblastoma.

Tumor Treating Field (TTF) therapy is anticipated to be the fastest-growing segment over the forecast period. Its growth is driven by increasing clinical adoption, favorable survival outcomes, and expanding regulatory approvals. TTF uses low-intensity alternating electric fields to disrupt cancer cell division, offering a non-invasive adjunct to standard therapy. Commercially available under Novocure’s Optune system, TTF is gaining traction across major markets due to proven efficacy in combination with temozolomide and expanding indications in recurrent and newly diagnosed GBM. Ongoing research into other solid tumors and supportive reimbursement frameworks are further accelerating market penetration and revenue growth.

End-use Insights

The hospitals segment held the majority share of 77.09% in 2024, due to the availability of advanced surgical infrastructure and multidisciplinary neuro-oncology care. Hospitals serve as primary treatment centers for glioblastoma patients, offering access to neurosurgery, radiotherapy, chemotherapy, and supportive care under one roof. The presence of highly skilled neurosurgeons, oncologists, and specialized nursing staff ensures comprehensive disease management. Integration of imaging, pathology, and clinical decision support systems further supports accurate diagnosis and treatment planning. Inpatient settings are especially vital for managing acute complications and postoperative recovery, driving the segment’s dominance in the GBM treatment landscape.

The clinics and outpatient centers segment is anticipated to be the fastest-growing channel over the forecast period. Growth is driven by the shift toward patient-centric care, shorter hospital stays, and cost-effective treatment delivery. Advancements in portable and home-based therapies, such as Tumor Treating Field (TTF) systems, enable outpatient management of GBM. Clinics and specialized outpatient centers offer improved access to novel therapies, supportive care, and multidisciplinary management, enhancing patient convenience and adherence. Expansion of specialized neuro-oncology clinics and reimbursement support further fuel growth, making this segment a key driver in the overall expansion of the GBM treatment landscape.

Regional Insights

North America glioblastoma multiforme treatment market held the largest global market share of 40.8% in 2024, driven by advanced oncology infrastructure and strong clinical adoption of novel therapies. The region leads due to early uptake of Tumor Treating Field (TTF) therapy, targeted agents, and immunotherapies. The U.S. dominates with the wide availability of temozolomide, bevacizumab, and Optune TTF systems, supported by specialized neuro-oncology centers. Collaborations between device makers, biotech firms, and leading cancer institutes are refining treatment protocols. Increasing focus on improving survival outcomes and expanding clinical trial activity supports North America’s continued market leadership.

U.S. Glioblastoma Multiforme Treatment Market Trends

The U.S. glioblastoma multiforme treatment dominated the North America region, supported by high healthcare expenditure and advanced cancer care facilities. Temozolomide-based chemoradiotherapy remains the standard of care, while Tumor Treating Field (TTF) therapy is gaining rapid adoption for newly diagnosed and recurrent GBM. Ongoing research into targeted therapies and immunotherapies is expanding treatment options. Leading cancer centers are integrating multimodal approaches combining surgery, chemoradiation, and device-based treatments. Strong reimbursement frameworks and clinical trial networks accelerate access. The U.S. market is poised to grow with continued innovation and expanding TTF and immunotherapy adoption.

Europe Glioblastoma Multiforme Treatment Market Trends

Europe’s glioblastoma multiforme treatment industry is expanding steadily due to increasing incidence and adoption of innovative therapies. Temozolomide combined with radiotherapy remains standard, while tumor treating fields and targeted agents gain adoption in specialized centers. Germany, France, and the UK lead in clinical research and implementation of novel treatment protocols. Strong neuro-oncology programs, multidisciplinary care models, and clinical trial participation support growth. Regulatory support through EU pathways enables quicker approvals for targeted therapies. Growing patient demand for personalized treatment and improved survival outcomes reinforces Europe’s significant market share.

The glioblastoma multiforme treatment industry in the UK is expanding due to the adoption of multimodal therapies and participation in clinical trials for novel agents. Temozolomide with radiotherapy is widely used, with increasing uptake of TTF therapy in specialized centers. NHS initiatives to improve cancer care pathways drive integration of advanced therapies. Research institutions are active in developing targeted and immunotherapeutic approaches for GBM. The focus on improving survival rates and quality of life is encouraging hospital investments in innovative devices and combination treatments. Clinical evidence supporting TTF therapy strengthens adoption in the UK.

Germany’s glioblastoma multiforme treatment industry is among the most advanced in Europe, supported by strong oncology infrastructure and research capabilities. Temozolomide-based regimens dominate first-line treatment, while TTF therapy is gaining clinical traction. German neuro-oncology centers lead in integrating device-based and molecular therapies. Collaborative research between hospitals, universities, and biotech firms fuels innovation. Patient demand for personalized GBM treatment and shorter hospital stays is driving the adoption of novel therapies. Germany’s robust regulatory and reimbursement framework further supports access to advanced treatments, ensuring sustained market growth.

The glioblastoma multiforme treatment industry in France is expanding with the integration of multimodal approaches in specialized oncology centers. Standard chemoradiotherapy with temozolomide remains dominant, supplemented by growing use of tumor-treating fields for eligible patients. Clinical trials exploring targeted and immunotherapies enhance the treatment pipeline. Hospitals prioritize combining therapies to extend survival and improve quality of life. Strong public healthcare funding supports access to innovative treatments. France’s active participation in European neuro-oncology research networks ensures continued advancement and adoption of cutting-edge GBM treatment strategies.

Asia Pacific Glioblastoma Multiforme Treatment Market Trends

The Asia-Pacific glioblastoma multiforme treatment industry is expected to register the fastest CAGR of 9.95% over the forecast period, driven by rising cancer prevalence and expansion of advanced oncology care. Increasing adoption of temozolomide and growing awareness of TTF therapy are key drivers. Japan leads adoption through integrated precision oncology programs, while China is expanding infrastructure for neuro-oncology care. Australia and South Korea show rapid uptake of novel therapies supported by clinical trial networks. Partnerships between global biotech companies and local hospitals accelerate technology transfer and treatment adoption across the region.

Japan’s glioblastoma multiforme treatment industry is expanding through strong integration of advanced oncology practices and research innovation. Temozolomide combined with radiotherapy is widely used, with TTF therapy adoption supported by advanced neurosurgical infrastructure. Hospitals integrate precision medicine approaches, and ongoing clinical trials broaden treatment options. Japan’s regulatory environment facilitates faster approvals for innovative therapies. Growing patient preference for non-invasive and home-based treatments drives TTF adoption. Collaborative efforts between academic centers and biotech firms strengthen Japan’s position as a key driver of growth in the Asia-Pacific GBM treatment market.

China’s glioblastoma multiforme treatment industry is growing rapidly due to rising incidence and expanding oncology infrastructure. Temozolomide remains standard, while emerging adoption of TTF therapy and clinical trials for targeted agents fuel growth. Investment in neuro-oncology centers and government healthcare initiatives enhances treatment access. Partnerships with international biotech and device manufacturers are expanding the treatment landscape. Growing awareness among clinicians and patients of advanced therapies supports adoption. China represents one of the fastest-growing GBM markets in Asia-Pacific due to large patient pools and increasing access to innovative treatment modalities.

Latin America Glioblastoma Multiforme Treatment Market Trends

The Latin America glioblastoma multiforme treatment industry is expanding steadily, driven by growing oncology infrastructure and increased access to advanced therapies. Temozolomide with radiotherapy remains standard care, while specialized centers begin adopting TTF therapy. Brazil and Mexico lead the market with increasing investment in neuro-oncology services. Collaboration with global biotech firms supports knowledge transfer and clinical adoption. The need to improve survival outcomes and access to cutting-edge therapies fuels growth. Latin America offers promising opportunities for infrastructure development and training programs that expand GBM treatment capabilities.

Brazil’s glioblastoma multiforme treatment industry is growing with rising demand for advanced neuro-oncology care. Temozolomide-based chemoradiotherapy dominates first-line treatment, while select cancer centers are adopting TTF therapy. Growing investment in oncology infrastructure in major metropolitan areas is improving access. Collaborations with global biotech companies enhance treatment availability. Hospitals focus on combining surgical resection with advanced adjuvant therapies to improve patient outcomes. Brazil holds a significant share of the Latin American GBM treatment market, supported by increasing awareness, clinical trial activity, and evolving healthcare policies.

Middle East & Africa Glioblastoma Multiforme Treatment Market Trends

The MEA glioblastoma multiforme treatment industry is developing, supported by expanding oncology infrastructure in key economies. Temozolomide-based treatment remains standard, with limited but growing adoption of TTF therapy in advanced cancer centers. Access to innovative therapies is concentrated in major hospitals in countries such as the UAE, Saudi Arabia, and South Africa. Partnerships with global biotech firms and device makers are enabling knowledge transfer and technology adoption. The growing focus on improving survival and quality of life for GBM patients, combined with increasing healthcare investments, supports gradual market growth in the MEA region.

The glioblastoma multiforme treatment industry in Saudi Arabia is expanding with rising investment in neuro-oncology and advanced cancer care facilities. Temozolomide remains the standard of care, while select centers adopt TTF therapy for eligible patients. Strong government initiatives to modernize oncology services, enabling greater access to innovative therapies. Collaboration between hospitals and international biotech firms is facilitating technology transfer. Growing awareness of advanced treatment options and increasing clinical trial activity further support growth. Saudi Arabia is emerging as a key market for GBM treatment in the Middle East, driven by healthcare modernization and expanding oncology capabilities.

Key Glioblastoma Multiforme Treatment Company Insights

Key players in the market are focusing on R&D to develop advanced products to gain a competitive edge. Merck & Co., Inc. and F. Hoffmann-La Roche Ltd. advanced targeted therapies and immuno-oncology agents for glioblastoma, focusing on molecular precision and survival extension. Amgen, Inc. and Pfizer Inc. emphasize the development of novel biologics and combination regimens to overcome the blood–brain barrier and improve treatment efficacy. Teva Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Ltd. concentrate on generic temozolomide and supportive care products to expand affordability and access. Arbor Pharmaceuticals, LLC, and Amneal Pharmaceuticals develop formulation innovations for optimized delivery. Karyopharm Therapeutics, Inc. and Sumitomo Dainippon Pharma Oncology, Inc. focus on next-generation small molecules and precision therapeutics, while clinical collaborations and trial networks drive adoption and pipeline advancement in the GBM treatment landscape.

Recent Developments

• In May 2025, Sumitomo Dainippon Pharma is progressing with Phase 1/2 clinical trials for DSP-0390, an emopamil-binding protein inhibitor, for the treatment of recurrent GBM. The drug targets key proteins involved in tumor cell survival and proliferation. The trials aim to assess DSP-0390's safety, tolerability, and efficacy in inhibiting GBM tumor growth, potentially providing a new therapeutic option for patients with recurrent high-grade gliomas.

• In January 2025, Merck is conducting Phase II clinical trials for pembrolizumab (Keytruda) in patients with recurrent GBM. The trials are investigating the drug both as a monotherapy and in combination with the DNX-2401 oncolytic virus. This clinical program aims to assess the potential of pembrolizumab to enhance the immune response against GBM tumors, a challenging cancer type with limited treatment options, particularly for recurrent cases.

• In January 2025, Pfizer’s Glasdegib, a Hedgehog pathway inhibitor, is in Phase II clinical trials for GBM. The drug targets the Hedgehog signaling pathway, which plays a crucial role in tumorigenesis and resistance to conventional therapies. The ongoing trials aim to evaluate the effectiveness of Glasdegib in GBM treatment and its potential to overcome treatment resistance and improve patient outcomes in recurrent cases of the disease.

Glioblastoma Multiforme Treatment Market Report Scope

Global Glioblastoma Multiforme Treatment Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global glioblastoma multiforme treatment market report based on treatment, end-use, and region:

• Treatment Outlook (Revenue, USD Million, 2021 - 2033)

  • Surgery

  • Radiation Therapy

  • Chemotherapy

    • Temozolomide

    • Lomustine

    • Carmustine Wafers

    • Other

  • Targeted Therapy

  • Tumor Treating Field (TTF) Therapy

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Clinics / Outpatient Centers

  • Ambulatory Surgical Centers

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait